Oral Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a chronic autoimmune intraepithelial vesiculobullous disease of the skin and mucous membranes. PV commonly affects the oral mucosa and it can be the initial site of presentation. Oral lesions present as painful ulcers preceded by bullae. The diagnosis of PV is based on clinical, histopathologic and immunopathologic examination. Systemic steroids are the mainstay of treatment for PV. This article reviews the etiology, pathogenesis, clinical presentations, diagnosis and management of PV.
1. Regezi JA, Sciubba JJ, Jordan RCK. Oral pathology. Clinical pathologic correlations. 4th ed. Philadelphia: Saunders; 2003: 11-15.
2. Ettlin DA. Pemphigus. Dent Clin North Am 2005; 49: 107-125.
3. Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 2002; 13: 397-408.
4. Black M, Mignogna MD, Scully C. Number II. Pemphigus vulgaris. Oral Dis 2005; 11: 119- 130.
5. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999; 140: 84-89.
6. กอบกาญจน์ ทองประสม. รอยโรคในช่องปากที่เกี่ยวข้องกับความผิดปกติของระบบภูมิคุ้มกัน. พิมพ์ครั้งที่ 2 สำนักพิมพ์แห่งจุฬาลงกรณ์มหาวิทยาลัย: กรุงเทพฯ; 2543: 99-117.
7. Mobini N, Yunis EJ, Alper CA, et al. Identical MHC markers in non-Jewish Iranian and Ashkenazi Jewish patients with pemphigus vulgaris: possible common central Asian ancestral origin. Hum Immunol 1997; 57: 62- 67.
8. Delgado JC, Yunis DE, Bozón MV, et al. MHC class II alleles and haplotypes in patients with pemphigus vulgaris from India. Tissue Antigens 1996; 48: 668-672.
9. Carcassi C, Cottoni F, Floris L, et al. HLA haplotypes and class II molecular alleles in Sardinian and Italian patients with pemphigus vulgaris. Tissue Antigens 1996; 48: 662-667.
10. Miyagawa S, Niizeki H, Yamashina Y, Kaneshige T. Genotyping for HLA-A, B and C alleles in Japanese patients with pemphigus: prevalence of Asian alleles of the HLA-B15 family. Br J Dermatol 2002; 146: 52-58.
11. Harman KE, Gratian MJ, Seed PT, Bhogal BS, Challacombe SJ, Black MM. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 2000; 25: 236-240.
12. Capon F, Bharkhada J, Cochrane NE, et al. Evidence of an association between desmoglein 3 haplotypes and pemphigus vulgaris. Br J Dermatol 2006; 154: 67-71.
13. Ayatollahi M, Joubeh S, Mortazavi H, Jefferis R, Ghaderi A. IgG4 as the predominant autoantibody in sera from patients with active state of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2004; 18: 241-242.
14. Iamaroon A, Boonyawong P, Klanrit P, Prasongtunskul S, Thongprasom K. Characterization of oral pemphigus vulgaris in Thai patients. J Oral Sci 2006; 48: 43-46.
15. Robinson NA, Yeo JF, Lee YS, Aw DC. Oral pemphigus vulgaris: a case report and literature update. Ann Acad Med Singapore 2004; 33: 63-68.
16. Thongprasom K, Korkij W. Oral pemphigus vulgaris: a study of 8 cases. CU Dent J 1999; 22: 61-66.
17. Salopek TG. Nikolsky’s sign: is it ‘dry’ or is it ‘wet’? Br J Dermatol 1997; 136: 762-767.
18. Maroni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 1059- 1062.
19. Vincent SD, Finkelstein MW. Differential diagnosis of oral ulcers. In: Coleman GC, Nelson JF, editors: Principle of oral diagnosis. St Louis: Mosby Year Book; 1993: 328-351.
20. Eversole LR. Immunopathology of oral mucosal ulcerative, desquamative and bullous diseases. Selective review of the literature. Oral Surg Oral Med Oral Pathol 1994; 77: 555-571.
21. Laskaris G. Oral pemphigus vulgaris: an immunofluorescent study of fifty-eight cases. Oral Surg Oral Med Oral Pathol 1981; 51: 626-631.
22. Challacombe SJ, Setterfield J, Shirlaw P, Harman K, Scully C, Black MM. Immunodiagnosis of pemphigus and mucous membrane pemphigoid. Acta Odontol Scand 2001; 59: 226-234.
23. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147: 261-265.
24. González-Moles MA, Scully C. Vesiculoerosive oral mucosal disease--management with topical corticosteroids: (1) Fundamental principles and specific agents available. J Dent Res 2005; 84: 294-301.
25. Stanley JR. Therapy of pemphigus vulgaris. Arch Dermatol 1999; 135: 76-78.
26. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5- year study. Int J Dermatol 1990; 29: 363-367.
27. Lozada F, Silverman S Jr, Migliorati C. Adverse side effects associated with prednisone in the treatment of patients with oral inflammatory ulcerative diseases. J Am Dent Assoc 1984; 109: 269-270.
28. Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 2002; 16: 353-356.
29. Mignogna MD, Lo Muzio L, Ruoppo E, Fedele S, Lo Russo L, Bucci E. High-dose intravenous ‘pulse’ methylprednisone in the treatment of severe oropharyngeal pemphigus: a pilot study. J Oral Pathol Med 2002; 31: 339-344.
30. Werth VP. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids. Arch Dermatol 1996; 132: 1435- 1439. 31. Posada F, Silverman S Jr.Topically applied fluocinonide in an adhesive base in the treatment of oral vesiculoerosive diseases. Arch Dermatol 1980; 116: 898-901.
32. Lozada-Nur F, Huang MZ, Zhou GA. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1991; 71: 283-287.
33. Lozada-Nur F, Miranda C, Maliksi R. Doubleblind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1994; 77: 598-604.
34. Singer NG, McCune WJ. Update on immunosuppressive therapy. Curr Opin Rheumatol 1998; 10: 169-173.
35. Olszewska M, Kolacinska-Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol 2007; 8: 85-92.
36. Roenigk HH Jr, Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol 1973; 107: 353-357.
37. Lozada-Nur F. Prednisolone and azathioprine in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol 1981; 52: 257-266.
38. Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? Arch Dermatol 1988; 124:1716-1718.
39. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003; 49: 276-280.
40. Mobini N, Padilla T Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997; 36: 264-266.
41. Coleman MD. Dapsone: mode of action, toxicity and possible strategies for increasing patient tolerance. Br J dermatol 1993; 129: 507-513.
42. Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent in maintenancephase pemphigus vulgaris. Arch Dermatol 2005; 141: 699-702.
43. Orfanos CE, Bauer R. Evidence for antiinflammatory activities of oral synthetic retinoids: experimental findings and clinical experience. Br J Dermatol 1983; 109 Suppl 25: 55-60.
44. Gaspar ZS, Walkden V, Wojnarowska F. Minocycline is a useful adjuvant therapy for pemphigus. Australas J Dermatol 1996; 37: 93-95.
45. Hodgson TA, Malik F, Hegarty AM, Porter SR. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol 2003; 13: 142-144.
46. Sami N, Bhol KC, Ahmed RA. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol 2003; 13: 377-381.
47. Herzog S, Schmidt E, Goebeler M, Bröcker EB, Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 2004; 84: 48-52.
48. Checchi L, D’Achille C, Zelent M. Desquamative gingivitis and chlorhexidine. Prev Assist Dent 1988; 14: 33-40.
49. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol 1979; 101: 521-534.
50. Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Sym Proc 2004; 9: 29-33.
51. Anhalt GJ. Paraneoplastic pemphigus: the role of tumours and drugs. Br J Dermatol 2001; 144: 1102-1104.
52. Kaplan I, Hodak E, Ackerman L, Mimouni D, Anhalt GJ, Calderon S. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations. Oral Oncol 2004; 40: 553-562.